EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Medicine overview — recent updates

PCWP meeting, EMA, 22 November 2017

Elizabeth Scanlan
Stakeholders and Communication Division

An agency of the European Union

Disclaimer

Medicine overview

Information about an authorised medicine is published as an **EPAR (European public assessment report**).

Key points are summarised in lay language in the medicine overview.

Public-friendly overview of the medicine and why it is authorised

Written by EMA, reviewed by experts, committee members and patients

Translated into all official EU languages

Where to find the overview



1. Go to EMA website (www.ema.europa.eu)
2. Type medicine name in ‘Find medicine’ search box

Value of patient/consumer review

- Unique **perspective**
- Patients and public **concerns**
- Appropriate use of **language**

Patient feedback

"The name EPAR summary does not mean anything to people outside EMA."

"It is important to convey that the medicine is under constant monitoring (pharmacovigilance)."

"Long introductory text is not needed."

"Where is the advice to read the PL or contact your doctor or pharmacist for more information?"

"Reduce references to committees and internal EMA and regulatory procedures."

"People do not know EMA and will not come to the EMA website for medicines information, but will go to unauthorised sources"

Updates

1. **Name change**: from **‘**EPAR summary for the public’ to ‘An overview of <medicine> and why it is authorised in the EU’
2. **Remove introduction** text, enhance **Search engine Optimisation**
3. **Remove mentions of committees / regulatory** processes
4. Point to package leaflet, advise to consult HCP in section about use of medicine
5. Text changes to increase **clarity and consistency**
6. Add information on **side effects monitoring**

EPAR summary for the public

Tecentriq

atezolizumab

This is a summary of the European public assessment report (EPAR) for Tecentriq. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice

For practical information about using Te
their doctor or pharmacist.

What is Tecentriq and what i

Tecentriq is a cancer medicine for treati
system) and a type of lung cancer calle

Tecentriq (*atezolizumab*)

An overview of Tecentriq and why it is authorised in the EU

What is Tecentriq and what is it used for?

Tecentriq is a cancer medicine for treating urothelial carcinoma (a cancer of the bladder and urinary system) and a type of lung cancer called non-small cell lung cancer.

Tecentriq is used when these cancers are advanced or have spread to other parts of the body. For urothelial carcinoma, the medicine is for patients who have tried platinum chemotherapy before or are ineligible for treatment with cisplatin. Patients with non-small cell lung cancer should first have had

How is Tecentriq used?

Tecentriq is given as an infusion (drip) into a vein every 3 weeks and treatment should continue for as long as the patient benefits from it or does not suffer from unmanageable side effects. Treatment may need t
bowel,
Tecent
experi
For mo
pharm

What measures are being taken to ensure the safe and effective use of Tecentriq?

The company that markets Tecentriq will put in place an educational program for patients and healthcare professionals to explain that serious immune-related side effects can occur during treatment and what they should do to minimize risks. The company is also carrying out and completing studies to provide more data on the effectiveness of Tecentriq in urothelial carcinoma and on the medicine's safety.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tecentriq have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tecentriq is continuously monitored. Side effects reported with Tecentriq are carefully evaluated and any necessary action taken to protect patients.

Other information about Tecentriq

The European Commission granted a marketing authorisation valid throughout the European Union for Tecentriq on 21 September 2017.



Other information about Tecentriq

Tecentriq received a marketing authorisation valid throughout the European Union on 21 September 2017.

Thank you for valuable patient and consumer feedback

Further information

Elizabeth.Scanlan@ema.europa.eu

European Medicines Agency
30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Follow us on **@EMA_News**